Caladrius Biosciences (CLBS) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free CLBS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineHARBOUR BIOMED LAUNCHES NONA BIOSCIENCES' "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATIONfinance.yahoo.com - December 1 at 12:07 AMCaladrius Biosciences (NASDAQ:CLBS) Now Covered by Analysts at StockNews.commarketbeat.com - September 20 at 3:40 AMCaladrius Biosciences, Inc.: Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeuticsfinanznachrichten.de - September 16 at 9:34 AMCaladrius Biosciences, Inc.: Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeuticsfinanznachrichten.de - September 15 at 6:33 PMCaladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeuticsfinance.yahoo.com - September 15 at 1:21 PMCLBS Caladrius Biosciences, Inc.seekingalpha.com - September 14 at 11:49 AMCaladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeuticsfinance.yahoo.com - September 14 at 11:49 AMHow to get the Protea Caladrius collection in Warframe: Veilbreakermsn.com - September 8 at 9:21 AMCaladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022finance.yahoo.com - September 8 at 9:21 AMCaladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancerfinance.yahoo.com - August 10 at 1:39 PMCaladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call Transcriptseekingalpha.com - August 5 at 12:38 AMCaladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Updatefinance.yahoo.com - August 4 at 7:38 PMSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates PING, CLBS, MANTmarkets.businessinsider.com - August 4 at 2:37 PMEarnings Outlook For Caladrius Biosciencesmsn.com - August 3 at 6:26 PMCaladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Diseasefinance.yahoo.com - August 2 at 10:03 AMCaladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Timefinance.yahoo.com - July 28 at 10:20 AMCaladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatologyfinance.yahoo.com - July 6 at 9:12 AMCaladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Groupfinance.yahoo.com - June 9 at 10:08 AMCaladrius Biosciences to Present at the BIO International Convention 2022finance.yahoo.com - June 8 at 8:27 AMCaladrius Biosciences and Cend Therapeutics Announce Poster Presentation at the 2022 American Society of Clinical Oncology Annual Meetingfinance.yahoo.com - May 26 at 10:11 AMCaladrius Biosciences Stops Enrollment In Mid-Stage Heart Disease Studyfinance.yahoo.com - May 24 at 12:36 PMCaladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunctionfinance.yahoo.com - May 23 at 9:01 PMmarketbeat.com - May 23 at 4:05 PMCaladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Diseasefinance.yahoo.com - May 19 at 6:24 PMCaladrius Biosciences to Present at the H.C. Wainwright Global Investment Conferencefinance.yahoo.com - May 18 at 11:47 AMCALADRIUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Caladrius Biosciences, Inc. - CLBSbenzinga.com - May 6 at 12:35 AMCaladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2022 Results - Earnings Call Transcriptseekingalpha.com - May 6 at 12:35 AMCaladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updatefinance.yahoo.com - May 5 at 7:35 PMCaladrius Biosciences Q1 2022 Earnings Previewseekingalpha.com - May 4 at 11:15 PMCALADRIUS BIOSCIENCES ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of CLBS and Encourages Investors to Contact the Firmbenzinga.com - May 2 at 2:30 PMCaladrius Biosciences, Incstockhouse.com - April 29 at 3:10 PMCaladrius Biosciences to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022, at 4:30 p.m. Eastern Timefinance.yahoo.com - April 28 at 9:19 AMCLBS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Caladrius Biosciences, Inc. Is Fair to Shareholdersapnews.com - April 28 at 12:49 AMCaladrius Biosciences To Merge With Privately-Held Cend Therapeuticsfinance.yahoo.com - April 27 at 7:48 PMCaladrius Biosciences David J. Mazzo, Current Pres and CEO of Caladrius, Will Be CEO of Lisata >CLBSmarketwatch.com - April 27 at 9:46 AMCaladrius Biosciences to merge with Cend Therapeuticsseekingalpha.com - April 27 at 9:46 AMmarketbeat.com - April 27 at 6:56 AMCaladrius Biosciences Treats First Patient In Phase 1b Trial Of CLBS201 For Treatment of Diabetic Kidney Diseasebenzinga.com - April 14 at 10:26 AMCaladrius treats 1st patient in phase 1b trial of cell therapy CLBS201 for diabetic kidney diseaseseekingalpha.com - April 12 at 10:34 AMCaladrius Biosciences Treats First Patient in the Phase 1b Trial of CLBS201 for the Treatment of Diabetic Kidney Diseasefinance.yahoo.com - April 12 at 10:34 AMHC Wainwright Trims Caladrius Biosciences (NASDAQ:CLBS) Target Price to $6.00marketbeat.com - March 23 at 7:51 AMRecap: Caladrius Biosciences Q4 Earningsbenzinga.com - March 23 at 3:08 AMCaladrius Biosciences GAAP EPS of -$0.11seekingalpha.com - March 22 at 5:06 PMCaladrius Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updatefinance.yahoo.com - March 22 at 5:06 PMCaladrius Biosciences Q4 2021 Earnings Previewseekingalpha.com - March 21 at 6:41 PMCaladrius Biosciences Earnings Previewbenzinga.com - March 21 at 6:41 PMCaladrius Biosciences to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 22, 2022, at 4:30 p.m. Eastern Timefinance.yahoo.com - March 15 at 1:47 PMCaladrius Biosciences Receives $2.3 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Programsg.finance.yahoo.com - March 1 at 4:25 PMCaladrius Biosciences Receives $2.3 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Programfinance.yahoo.com - March 1 at 4:25 PMLongeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directorsfinance.yahoo.com - February 17 at 8:08 AM Get Caladrius Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLBS and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers. Find out why right here (and see what you can do to get in too with just a few dollars). CLBS Media Mentions By Week CLBS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLBS News Sentiment▼0.000.40▲Average Medical News Sentiment CLBS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLBS Articles This Week▼00▲CLBS Articles Average Week Get Caladrius Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLBS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ACXP News ALRN News EYEN News MOVE News SLGL News CERO News NKGN News FBRX News UBX News LPCN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLBS) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caladrius Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
